Surgery of Advanced Tumors
Author (ref) Year No. of patients Operative mortality % Survival rates, 5 years (%) Overall NO N1 N2 Piehler [8] 1982 66 15.2 32.9 54.0 7.4a 7.4a Patterson [9] 1982…
Bone Metastases
Fig. 15.1 Zoledronic acid reduced percentage of patients with each SRE. Phase III trial of patients with bone metastases from NSCLC/OST who received ZOL or placebo every 3 weeks for…
New Approaches in Immunotherapy
and Martin Reck1 (1) Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Woehrendamm 80, 22927 Grosshansdorf, Germany Introduction Non-small…
How to Personalize Chemotherapy in Stage IV NSCLC?
Fig. 8.1 Homologous recombination and nonhomologous end joining process Furthermore, inhibition of RNF8 activity can suppress BRCA1, independent of HR in tumor cells with low 53BP1, and RNF8 could establish…
Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer
Fig. 11.1 RAS protein GTPase activation and inactivation [7] Mutation in the RAS proto-oncogene, one of the most common mutations in NSCLC, is found in 15–30 % NSCLC. Most RAS…
Brain Metastases
and Frederic Dhermain1 (1) Department of Radiation Oncology, Gustave Roussy University Hospital, 114 rue e veillant, 94850 Villejuif, France Introduction Brain metastases are frequent in the natural history of malignant tumours…
Integrated PET/CT and Linear Endosonography (EBUS and EUS)
Study N Population Study question Comparison Findings Fischer 189 Resectable stage I-III NSCLC Number of ‘futile thoracotomies’ CS - > S 52 % vs. 35 % (P = 0.05) PET-CT - > S Maziak 337 Resectable…
How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?
Fig. 5.1 The ITACA (International Tailored Chemotherapy Adjuvant Trial), a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stages II–IIIA NSCLC From…
